Bristol Myers Squibb has entered a global collaboration with Harbour BioMed worth up to $1.1B to discover and develop next-generation multispecific antibodies, strengthening its early-stage immunology and oncology pipeline.
Genentech has signed a multi-year oncology collaboration with Caris Life Sciences worth up to $1.1B, tapping the techbio’s AI-driven tumor database to discover new solid-tumor targets as year-end dealmaking accelerates.
The Institute for Clinical and Economic Review (ICER) has delivered a strong clinical and economic endorsement of today’s leading obesity drugs, while simultaneously warning that U.S. payers are unprepared for the scale of demand these therapies are likely to generate. In a final evidence report released Tuesday, ICER concluded that Novo Nordisk’s semaglutide (Wegovy, injectable … Read more
The neurology landscape advanced on multiple fronts today, spanning rare pediatric disease regulation, progressive multiple sclerosis setbacks, epilepsy drug financing, augmented-reality–guided neurosurgery, and expanded commercial reach for psychiatric therapies in Asia. Together, these developments reflect a field balancing regulatory scrutiny with accelerating innovation, particularly in rare disorders, surgical precision, and infrastructure that shortens the path … Read more
Zealand Pharma’s up-to-$2.5B collaboration with OTR Therapeutics highlights a strategic pivot in metabolic drug development.
Yarrow lands $1.37B China biotech deal, betting on first-in-class TSHR antibody for thyroid disease U.S.-based Yarrow Bioscience has secured its lead asset through a potential $1.37 billion licensing deal with China’s GenSci Pharmaceutical, picking up ex-China rights to a first-in-class antibody targeting autoimmune thyroid disease as it charts a broader expansion beyond its early platform … Read more
Sanofi has signed a global licensing agreement worth up to about $1.04 billion for an early-stage Alzheimer’s antibody targeting acetylated tau, marking the pharma’s second biotech deal of the day as it accelerates external pipeline building in neurology.
Dren Bio has expanded its strategic collaboration with Sanofi in a deal worth up to $1.8 billion, advancing next-generation B-cell depletion therapies and reinforcing deep-remission strategies in autoimmune disease.
Swedish orphan-drug specialist Sobi has agreed to acquire Arthrosi, a privately held biotech focused on next-generation gout therapies
The EU has finalized a sweeping Pharma Package deal, preserving eight years of data protection, adding new antibiotic incentives and giving member states new powers to secure medicine supply.